RU2012157399A - Пептиды в качестве активных агентов для стабилизации биологических барьеров - Google Patents
Пептиды в качестве активных агентов для стабилизации биологических барьеров Download PDFInfo
- Publication number
- RU2012157399A RU2012157399A RU2012157399/04A RU2012157399A RU2012157399A RU 2012157399 A RU2012157399 A RU 2012157399A RU 2012157399/04 A RU2012157399/04 A RU 2012157399/04A RU 2012157399 A RU2012157399 A RU 2012157399A RU 2012157399 A RU2012157399 A RU 2012157399A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- peptide according
- group
- amino acid
- peptide
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 37
- 239000013543 active substance Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 230000000087 stabilizing effect Effects 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 12
- 150000001413 amino acids Chemical class 0.000 claims abstract 8
- 102000009027 Albumins Human genes 0.000 claims abstract 2
- 108010088751 Albumins Proteins 0.000 claims abstract 2
- 229920002307 Dextran Polymers 0.000 claims abstract 2
- 102000008857 Ferritin Human genes 0.000 claims abstract 2
- 238000008416 Ferritin Methods 0.000 claims abstract 2
- 108050000784 Ferritin Proteins 0.000 claims abstract 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims abstract 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims abstract 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims abstract 2
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 2
- 230000000694 effects Effects 0.000 claims abstract 2
- 108010001279 glycyl-arginyl-arginyl-prolyl-leucyl-glycyl-glycyl-isoleucyl-seryl-glycyl-glycine Proteins 0.000 claims abstract 2
- 229940050526 hydroxyethylstarch Drugs 0.000 claims abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 2
- 102000007268 rho GTP-Binding Proteins Human genes 0.000 claims abstract 2
- 108010033674 rho GTP-Binding Proteins Proteins 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 206010069351 acute lung injury Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 5
- 208000033626 Renal failure acute Diseases 0.000 claims 5
- 208000010285 Ventilator-Induced Lung Injury Diseases 0.000 claims 5
- 201000011040 acute kidney failure Diseases 0.000 claims 5
- 230000009885 systemic effect Effects 0.000 claims 5
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 4
- 206010040047 Sepsis Diseases 0.000 claims 4
- 230000004064 dysfunction Effects 0.000 claims 4
- 230000008497 endothelial barrier function Effects 0.000 claims 4
- 230000004890 epithelial barrier function Effects 0.000 claims 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 3
- 230000001154 acute effect Effects 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 231100000516 lung damage Toxicity 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ATA1010/2010 | 2010-06-18 | ||
| AT10102010 | 2010-06-18 | ||
| PCT/EP2011/060105 WO2011157819A2 (en) | 2010-06-18 | 2011-06-17 | Peptides as active agents to stabilize biological barriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012157399A true RU2012157399A (ru) | 2014-07-27 |
Family
ID=44628513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012157399/04A RU2012157399A (ru) | 2010-06-18 | 2011-06-17 | Пептиды в качестве активных агентов для стабилизации биологических барьеров |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9012403B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2582720B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5709985B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103038253A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2802635A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2486321T3 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2012157399A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011157819A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103068400A (zh) | 2010-06-25 | 2013-04-24 | 阿斯顿大学 | 具有脂类动员性质的糖蛋白及其治疗用途 |
| WO2015022326A1 (en) | 2013-08-12 | 2015-02-19 | Xiber Science Gmbh | Peptides as active agents for treating primary graft dysfunction |
| NL2015130B1 (en) * | 2015-07-09 | 2017-02-01 | Mimetas B V | Barrier function measurements. |
| EP3436070A4 (en) * | 2016-03-29 | 2019-11-27 | University of Southern California | AGAINST CANCER, CHIMERIC ANTIGEN RECEPTORS |
| MX2021001877A (es) * | 2018-08-17 | 2021-07-15 | Univ Pennsylvania | Composiciones y métodos para el tratamiento de lesión pulmonar aguda. |
| US20220062391A1 (en) * | 2019-01-16 | 2022-03-03 | University Of Rochester | Enhancing epithelial or endothelial barrier function |
| EP4093423A1 (en) | 2020-01-22 | 2022-11-30 | UCL Business Ltd | Peptide inhibitors of guanine nucleotide exchange factor-h1 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| EP0052322B1 (de) | 1980-11-10 | 1985-03-27 | Gersonde, Klaus, Prof. Dr. | Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4711955A (en) | 1981-04-17 | 1987-12-08 | Yale University | Modified nucleotides and methods of preparing and using same |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| CA1223831A (en) | 1982-06-23 | 1987-07-07 | Dean Engelhardt | Modified nucleotides, methods of preparing and utilizing and compositions containing the same |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| DE3483949D1 (de) | 1983-09-26 | 1991-02-21 | Udo Dr Med Ehrenfeld | Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr. |
| EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
| US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
| US20040053250A1 (en) * | 2001-03-05 | 2004-03-18 | Tang Y. Tom | Novel arginine-rich protein-like nucleic acids and polypeptides |
| EP1519957B1 (en) * | 2002-07-03 | 2009-03-04 | Fondazione Centro San Raffaele Del Monte Tabor | Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| AU2007223888A1 (en) | 2006-03-06 | 2007-09-13 | Amunix, Inc. | Genetic packages and uses thereof |
| EA021222B8 (ru) | 2007-06-21 | 2015-11-30 | ИксЭль-ПРОТЕИН ГМБХ | Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro |
-
2011
- 2011-06-17 CN CN2011800299272A patent/CN103038253A/zh active Pending
- 2011-06-17 CA CA2802635A patent/CA2802635A1/en not_active Abandoned
- 2011-06-17 RU RU2012157399/04A patent/RU2012157399A/ru not_active Application Discontinuation
- 2011-06-17 ES ES11732400.4T patent/ES2486321T3/es active Active
- 2011-06-17 EP EP11732400.4A patent/EP2582720B1/en not_active Not-in-force
- 2011-06-17 WO PCT/EP2011/060105 patent/WO2011157819A2/en not_active Ceased
- 2011-06-17 JP JP2013514731A patent/JP5709985B2/ja not_active Expired - Fee Related
- 2011-06-17 US US13/702,490 patent/US9012403B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2802635A1 (en) | 2011-12-22 |
| ES2486321T3 (es) | 2014-08-18 |
| EP2582720A2 (en) | 2013-04-24 |
| WO2011157819A3 (en) | 2012-02-23 |
| JP2013529916A (ja) | 2013-07-25 |
| EP2582720B1 (en) | 2014-05-21 |
| US9012403B2 (en) | 2015-04-21 |
| CN103038253A (zh) | 2013-04-10 |
| JP5709985B2 (ja) | 2015-04-30 |
| WO2011157819A2 (en) | 2011-12-22 |
| US20130143791A1 (en) | 2013-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012157399A (ru) | Пептиды в качестве активных агентов для стабилизации биологических барьеров | |
| US11524048B2 (en) | HMGB1 antagonist treatment of severe sepsis | |
| JP2023130345A (ja) | ＥｐｈＡ２に特異的な二環ペプチドリガンド | |
| JP2021046436A (ja) | ペプチド模倣大環状分子およびその製剤 | |
| EP2983695B1 (en) | Methods, uses and compositions of tie2 agonists | |
| JP2015518818A5 (cg-RX-API-DMAC7.html) | ||
| JP2019533722A5 (cg-RX-API-DMAC7.html) | ||
| JP2015134758A5 (cg-RX-API-DMAC7.html) | ||
| HRP20110242T1 (hr) | Formulacija s fuzijskim proteinom glp-1-fc | |
| JP2015504870A (ja) | 線維症を処置するためのアンジオテンシン | |
| JP2015513318A5 (cg-RX-API-DMAC7.html) | ||
| JP2006506942A5 (cg-RX-API-DMAC7.html) | ||
| US20230039219A1 (en) | Improved Cell-Permeable Nuclear Import Inhibitor Synthetic Peptide for Inhibition of Cytokine Storm or Inflammatory Disease and Use Thereof | |
| JP2017526627A5 (cg-RX-API-DMAC7.html) | ||
| JP2023517616A (ja) | 急性呼吸窮迫症候群およびウイルス感染の治療用のｃｘｃｒ４阻害剤 | |
| JP2013529916A5 (cg-RX-API-DMAC7.html) | ||
| US20220257714A1 (en) | Use of dermcidin in sterile inflammatory conditions | |
| JP2024539138A (ja) | 多価効果を持つペプチド | |
| RU2018112060A (ru) | Слитый белок | |
| US11571455B2 (en) | Methods and compositions for treating alcoholic liver disease | |
| JP2020536934A5 (cg-RX-API-DMAC7.html) | ||
| JP2017508806A5 (cg-RX-API-DMAC7.html) | ||
| US11883461B2 (en) | HMGB1 antagonist treatment of severe sepsis | |
| US11376306B2 (en) | Peptides and uses therefor as antiviral agents | |
| RU2005123050A (ru) | Супер-антигенные фьюжн-белки и их использование |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20160627 |